Epiomed Therapeutics Obtains Series A Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=87c1621d-6d09-42e7-a8c5-110b4f2795bf&Preview=1 - Date
6/8/2011 - Company Name
Epiomed Therapeutics - Mailing Address
25 Mauchly Irvine, CA 92618 - Company Description
The company is developing novel, small molecule anti-emetic and anti-motion sickness compounds. - Website
http://www.epiomed.com - Transaction Type
Venture Equity - Transaction Amount
Undisclosed - Transaction Round
Series A - Proceeds Purposes
Proceeds from this financing are anticipated to be used for development of Epiomed’s lead anti-emetic compound, designated “ETI-0001” with a Phase 1/2 clinical assessment of ETI-0001 anticipated starting in 1Q 2012. - M&A Terms
- Venture Investor
Undisclosed
